 |
fixed dose combination of methimazole and liothyronine |
|---|---|
| Trade Name | |
| Orphan Indication | Brain metastases in patients with primary lung cancer |
| USA Market Approval | USA |
| USA Designation Date | 2017-03-06 00:00:00 |
| Sponsor | Musli Thyropeutics Ltd.;6 Hagefen Street, P. O. Box 529;Zur Moshe |
